Data Sheet (Cat.No.T15056)




DB07107

Chemical Properties

CAS No.: 552332-71-5 Formula: C23H22N4O

Molecular Weight: 370.45
Appearance: N/A

Storage: 0-4°C for short term (days to weeks), or -20°C for long term (months).



Biological Description

Description	DB07107 is a potent inhibitor of drug resistant T315I mutant Bcr-Abl tyrosine kinase and a potent Akt1 inhibitor (IC50: 360 nM).
Targets(IC ₅₀)	Akt1: 360 nM
In vitro	DB07107 from DrugBank showed the highest binding energy (XP: -14.045 kcal/mol). DB07107 is more potent in blocking drug-resistant T315I mutant than the wild-type Bcr-Abl [1].

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.699 mL	13.497 mL	26.994 mL
5 mM	0.54 mL	2.699 mL	5.399 mL
10 mM	0.27 mL	1.35 mL	2.699 mL
50 mM	0.054 mL	0.27 mL	0.54 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

- 1. Banavath HN, et al. Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study. Sci Rep. 2014 Nov 10;4:6948.
- 2. Li Q, et al. Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. Bioorg Med Chem Lett. 2006 Mar 15;16(6):1679-85.

Page 1 of 2 www.targetmol.com

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only \cdot Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com